Taiho Oncology, Inc.
Said P. Rahal has an extensive work experience in the field of pharmacovigilance. They began their career at Novartis in 2003 as a Senior Clinical Safety Scientist/Therapeutic Team Lead Drug Safety and worked there until 2008. They then joined Sanofi-Aventis as a Global Pharmacovigilance Trainer until 2010. Following this, they worked at Ranbaxy as a Drug Safety professional for a year. In 2011, they joined MedImmune as a Sr. Manager in Patient Safety and stayed there until 2013. They then joined Mitsubishi Tanabe Pharma Corporation as an Associate Director & Head of Quality, Standards, and Training in Drug Safety. In 2015, Said joined Vertex Pharmaceuticals as the Director of Global Patient Safety until 2016. They then worked at Teva Pharmaceuticals as a Global Pharmacovigilance Compliance Team Leader from 2016 to 2017. Currently, they are working at Taiho Oncology, Inc. as the Vice President of Pharmacovigilance, a role they started in January 2022. Previously, at Taiho Oncology, Inc., they held the position of Senior Director in Pharmacovigilance Quality, Standards & Training (QST) and Head of PV Operations from 2017 to 2022.
Said P. Rahal holds an MBA in International Business from Walden University. Additionally, Rahal obtained a Bachelors of Science in Nursing from Bloomfield College. No further information is available regarding the start and end years of these educational pursuits.
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com